## Jean-Paul Viard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/453039/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prevalence of Silent Atherosclerosis and Other Comorbidities in an Outpatient Cohort of Adults Living with HIV: Associations with HIV Parameters and Biomarkers. AIDS Research and Human Retroviruses, 2021, 37, 101-108.	1.1	3
2	Tenofovir disoproxil fumarate and emtricitabine maintenance strategy in virologically controlled adults with low HIV-1 DNA: 48 week results from a randomized, open-label, non-inferiority trial. Journal of Antimicrobial Chemotherapy, 2021, 76, 1564-1572.	3.0	2
3	Factors Associated With Being Overweight and Obesity in People Living With Human Immunodeficiency Virus on Antiretroviral Therapy: Socioclinical, Inflammation, and Metabolic Markers. Journal of Infectious Diseases, 2021, 224, 1570-1580.	4.0	2
4	HIV infection and COVID-19: risk factors for severe disease. Aids, 2020, 34, 1771-1774.	2.2	64
5	Perspectives of injectable long acting antiretroviral therapies for HIV treatment or prevention: understanding potential users' ambivalences. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 155-161.	1.2	21
6	Increasing contribution of integrated forms to total HIV DNA in blood during HIV disease progression from primary infection. EBioMedicine, 2019, 41, 455-464.	6.1	12
7	Long-term Therapeutic Impact of the Timing of Antiretroviral Therapy in Patients Diagnosed With Primary Human Immunodeficiency Virus Type 1 Infection. Clinical Infectious Diseases, 2018, 66, 1519-1527.	5.8	25
8	Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial. Journal of Antimicrobial Chemotherapy, 2018, 73, 1020-1024.	3.0	1
9	Population Pharmacokinetic Modeling of Tenofovir in the Genital Tract of Male HIV-Infected Patients. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	5
10	Gag-Specific CD4 T Cell Proliferation, Plasmacytoid Dendritic Cells, and Ethnicity in Perinatally HIV-1-Infected Youths: The ANRS-EP38-IMMIP Study. AIDS Research and Human Retroviruses, 2017, 33, 21-28.	1.1	1
11	Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals. Journal of Antimicrobial Chemotherapy, 2017, 72, 3167-3171.	3.0	8
12	Gag-Specific CD8 T-Cell Proliferation Is Associated With Higher Peripheral Blood Levels of Transforming Growth Factor-β and Gut-Homing T Cells in Youths Perinatally Infected With Human Immunodeficiency Virus-1: The ANRS-EP38-IMMIP Study. Open Forum Infectious Diseases, 2017, 4, ofw239.	0.9	0
13	Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications. Clinical Microbiology Reviews, 2016, 29, 859-880.	13.6	185
14	Vitamin D Deficiency and Infection in Chronic Kidney Disease. , 2016, , 295-304.		0
15	Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial. AIDS Research and Therapy, 2016, 13, 17.	1.7	8
16	Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression. Journal of Antimicrobial Chemotherapy, 2016, 71, 751-761.	3.0	18
17	No Positive Association between Vitamin D Level and Immune Responses to Hepatitis B and Streptococcus pneumoniae Vaccination in HIV-Infected Adults. PLoS ONE, 2016, 11, e0168640.	2.5	8
18	Risk of HIV Transmission Under Combined Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, e41-e42.	2.1	2

#	Article	IF	CITATIONS
19	Gag-Specific CD4 and CD8 T-Cell Proliferation in Adolescents and Young Adults with Perinatally Acquired HIV-1 Infection Is Associated with Ethnicity — The ANRS-EP38-IMMIP Study. PLoS ONE, 2015, 10, e0144706.	2.5	2
20	Emtricitabine Seminal Plasma and Blood Plasma Population Pharmacokinetics in HIV-Infected Men in the EVARIST ANRS-EP 49 Study. Antimicrobial Agents and Chemotherapy, 2015, 59, 6800-6806.	3.2	15
21	Predictive value of prostate-specific antigen for prostate cancer: a nested case-control study in EuroSIDA. Journal of the International AIDS Society, 2014, 17, 19510.	3.0	1
22	Heterosexual Risk of HIV Transmission per Sexual Act Under Combined Antiretroviral Therapy: Systematic Review and Bayesian Modeling. Clinical Infectious Diseases, 2014, 59, 115-122.	5.8	30
23	Prognostic Value of Vitamin D Level for All-cause Mortality, and Association With Inflammatory Markers, in HIV-infected Persons. Journal of Infectious Diseases, 2014, 210, 234-243.	4.0	42
24	Population Pharmacokinetics of Emtricitabine in HIV-1-Infected Adult Patients. Antimicrobial Agents and Chemotherapy, 2014, 58, 2256-2261.	3.2	40
25	Vitamin D supplementation is associated with reduced immune activation levels in HIV-1-infected patients on suppressive antiretroviral therapy. Aids, 2014, 28, 2677-2682.	2.2	30
26	Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4). International Journal of Epidemiology, 2014, 43, 1425-1436.	1.9	70
27	HIV-1 DNA Levels in Peripheral Blood Mononuclear Cells and Cannabis Use are Associated With Intermittent HIV Shedding in Semen of Men Who Have Sex With Men on Successful Antiretroviral Regimens. Clinical Infectious Diseases, 2014, 58, 1763-1770.	5.8	44
28	Role of vitamin D in acquired immune and autoimmune diseases. Critical Reviews in Clinical Laboratory Sciences, 2014, 51, 232-247.	6.1	48
29	Naive T Lymphocytes and Recent Thymic Emigrants Are Associated With HIV-1 Disease History in French Adolescents and Young Adults Infected in the Perinatal Period: The ANRS-EP38-IMMIP Study. Clinical Infectious Diseases, 2014, 58, 573-587.	5.8	17
30	The Kidney as a Reservoir for HIV-1 after Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2014, 25, 407-419.	6.1	121
31	Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study. PLoS Pathogens, 2013, 9, e1003211.	4.7	879
32	Long-term antiretroviral therapy initiated during primary HIV-1 infection is key to achieving both low HIV reservoirs and normal T cell counts. Journal of Antimicrobial Chemotherapy, 2013, 68, 1169-1178.	3.0	208
33	Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia. Aids, 2013, 27, 2425-2430.	2.2	41
34	Is Clinical Practice Concordant with the Changes in Guidelines for Antiretroviral Therapy Initiation during Primary and Chronic HIV-1 Infection? The ANRS PRIMO and COPANA Cohorts. PLoS ONE, 2013, 8, e71473.	2.5	13
35	Associations between 25-Hydroxyvitamin D and Immunologic, Metabolic, Inflammatory Markers in Treatment-Naive HIV-Infected Persons: The ANRS CO9 «COPANA» Cohort Study. PLoS ONE, 2013, 8, e74868.	2.5	26
36	Immune Deficiency Could be An Early Risk Factor for Altered Insulin Sensitivity in Antiretroviral-Naive HIV-1-Infected Patients: The Anrs Copana Cohort. Antiviral Therapy, 2012, 17, 91-100.	1.0	22

JEAN-PAUL VIARD

#	Article	IF	CITATIONS
37	Effect of Alendronate on HIV-Associated Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled, 96-Week Trial (ANRS 120). AIDS Research and Human Retroviruses, 2012, 28, 972-980.	1.1	36
38	Relationships Between HIV Disease History and Blood HIV-1 DNA Load in Perinatally Infected Adolescents and Young Adults: The ANRS-EP38-IMMIP Study. Journal of Infectious Diseases, 2012, 205, 1520-1528.	4.0	26
39	Effect of intermittent interleukin-2 therapy on CD4+ T-cell counts following antiretroviral cessation in patients with HIV. Aids, 2012, 26, 711-720.	2.2	20
40	Presentation of HIV-associated nephropathy and outcome in HAART-treated patients. Nephrology Dialysis Transplantation, 2012, 27, 1114-1121.	0.7	46
41	Prevalence of Low Bone Mineral Density in Men and Women Infected With Human Immunodeficiency Virus 1 and a Proposal for Screening Strategy. Journal of Clinical Densitometry, 2012, 15, 422-433.	1.2	19
42	Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. Aids, 2011, 25, 1305-1315.	2.2	157
43	Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. Aids, 2010, 24, 1598-1601.	2.2	179
44	Higher HIV-1 DNA associated with lower gains in CD4 cell count among patients with advanced therapeutic failure receiving optimized treatment (ANRS 123ETOILE). Journal of Antimicrobial Chemotherapy, 2010, 65, 2212-2214.	3.0	17
45	Enhanced T cell recovery in HIV-1–infected adults through IL-7 treatment. Journal of Clinical Investigation, 2009, 119, 997-1007.	8.2	288
46	HIV infection impairs CCR7-dependent T-cell chemotaxis independent of CCR7 expression. Aids, 2009, 23, 1197-1207.	2.2	10
47	Factors influencing peripheral blood mononuclear cell-associated HIV-1 DNA level after long-term suppressive antiretroviral therapy in 236 patients. Aids, 2009, 23, 2165-2171.	2.2	31
48	Quantification of seven nucleoside/nucleotide reverse transcriptase inhibitors in human plasma by high-performance liquid chromatography with tandem mass-spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 865, 81-90.	2.3	57
49	Early Levels of HIVâ€1 DNA in Peripheral Blood Mononuclear Cells Are Predictive of Disease Progression Independently of HIVâ€1 RNA Levels and CD4+T Cell Counts. Journal of Infectious Diseases, 2005, 192, 46-55.	4.0	163
50	Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. Aids, 2004, 18, 45-49.	2.2	151
51	Presence of HIV-Specific CD4+ T-Cell Responses in HIV-Infected Subjects With Sustained Virologic Control After Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 36, 594-599.	2.1	8
52	Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. Aids, 2004, 18, 1958-1961.	2.2	93
53	Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV-infected men. Aids, 2004, 18, 447-457.	2.2	75